Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The stock went up 22 % on volume of 150000.
When there is a trade, there is always a seller, however, if there are not many sellers than the price goes up.
wow, up 22% on no volume at all. There were no sellers!
Some days they want to buy, and other days they want to sell.
Sometimes it rains
Sometimes it pours
Sometimes you play baseball.
I know where this is. Where are they going to put Phenoguard now?
There is room for MANF, and ESS, but not Phenoguard.
I agree.
Great trade though, if the general news was not so bad, I would have bitten. The pps based for a very long time, the chart was perfect for some good news.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=AMBS&insttype=Stock&freq=1&show=&time=13
That was a very good day a few years ago, when I got folks out at 18 cents.
18 times 150 equals $27
The reverse split came later.
shades of 2012 and then 2015. ( Whenver the stock peaked at 18 cents pre RS. )
Very nice straw man argument.
not
I figured that.
On the back of a successful early study they will either sell stock or a piece of the future earnings in the compound to fund the later development.
$50 million will not buy you lunch in pharma.
How long is the Phase 2 study supposed to last?
THREE YEARS. JUST FOR THE PHASE 2 study.
Now, I know it will not take three years, but overall, it will be more than three to get ESS to market.
READ THIS
https://clinicaltrials.gov/ct2/show/NCT01655407
btw, the study director is noted in that link. If ONE PERSON wants to call him JP, he will know when the study will begin.
I live here at FDA headquarters. I have several friends who do this. It will cost a billion.
The average for a compound is $800 million. MANF is involved with brain infusions.
They are not just going to let folks do that without 2 phase III studies.
not just money but serious money is needed for MANF. You are looking at Billions, and something like 6-8 years. The only way to speed that up is to find an indication with an unmet need.
There goes five years of waiting.
The posts are starting to sound very hopeful again.
ESS is three to four years and it is in stage 2.
It also depends on where you bought. Getting back to the peak is not very likely any time soon. In between there was a 150 to one RS.
The Market cap is under five million.
Keeping in mind I have not done the due diligence.
This move by SeD tends to say the company is not going away.
If I read it correctly, they are paying the company debts. In addition they have money to spend on research.
The only thing I would research is ESS for now, since it is real and will make money.
After that, if you are sure that this move will save the company, then there is reason to buy on the dip, based on just ESS. ESS is worth more than five million.
MANF could be worth something if someone wants to spend a Billion dollars on it. Or it could be worthless. If you have a spare Billion, I will help you spend it.
The rest will not be researched by a reputable company. Only a company looking to generate fees for themselves would get those entities. We did not know that was going on at the time, and so that is why that happened. Great, buy this, and get paid, good idea, lets do another one.
That is what happened.
So, what is this going to do to the stock?
I just want someone to get ESS so that it can get to the patients. This is a ridiculous delay in research.
$7000 dollars worth of AMBS.
follow the money.
what did he know?
when did he know it?
is there any money left?
I want some money.
Yes, I think GC knew exactly what he was doing.
He saw the bonuses, and a small little nest egg, instead of a giant nest egg, that was never possible.
I do not believe the bonuses came out until the total compensation for the year, over 600K was made public.
Of course, I got out, got my brother out, and a lot of people at 18 cents pre RS, all the while noting that this was a scam and taking a lot of heat for it.
Ride the wave I always say.
We only missed one cent of upside on that one.
I've been using my trampoline regularly, and wondering if it might break one day. You see, I got it used from this guy.
AMBS has two assets, only one is close to the market. That is ESS.
MANF should continue to be a research interest. Once somoene puts a billion or more dollars into its research they will figure out if it has any therapeutic use.
Think about a Billion dollars for EACH therapeutic use, more or less.
That all comes before you see any cash for the asset.
ESS is the only asset of AMBS that can bring any cash in the next five years. That will take about five years to monetize. It should be less than that, but well, things do move slowly.
The days of folks actually believing lines like, there will be cash this year from MANF are long gone.
Eltoprazine
All of the tests
Neuropro
MANF for RP, WOlframs
Are all useless.
Phenoguard also has lots of ressearch potential. Again billions are needed for that one.
Ok, same thing. different skin.
I will say a prayer, and jump up and down on my trampoline.
why not.
There is no there, there, there isn't even anyone to file for bankruptcy, there is no nothing.
I wonder what happens now?
We just forget AMBS ever existed.
Big money, $31000, more or less.
The chart is matching up with the bid.
I only ever liked this company for the chart.
On the other hand, I wish that I had bought before I said that, because people do listen to me now that well, I've been right for the better part of five years.
Which was the point in the first place.
Keep in mind there were caveats to that positive comment.
http://www.sciencedirect.com/science/journal/05315565
Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition
Original Research Article
Pages 45-56
Jingxing Zhang, Qiong Cai, Ming Jiang, Yigang Liu, Hua Gu, Jia Guo, Hui Sun, Jianmin Fang, Lingjing Jin
This is very interesting. It makes MANF worth some money. If someone wants to pursue this.
That is, if this can be replicated. That is the important part.
And it does not mean that this is clinically important. However, it could be clinically important.
By the note on the science direct page, this is an issue in progress. For some reason they publish the monthly issue a bit at a time. As the articles get OKd for publication.
Based on MANF history, I would wait for the follow up study. It sounds to much like GC.
I was referring to my prediction that the company would post a Q before the end of 2016.
The only thing that has not happened yet, is the posting of a Q. There is nothing more that can happen.
I am thinking that AMBS could not pay Stanford the cash needed to rent the factilities, nor could they pay the attendees to come and present, and so on.
but i could have gotten 7% on friday if I was in this stock.
Seriously, I am off by at least 23 days. The company is really dead, they have just not made the announcement yet.
Here it goes, To the Moon!!! That is where they send stocks to die. best of luck with your company.
They could be going by the alphabet.
Amarantus is the lead sponsor.
Yes, he kept up the lie about that, and kept denying the Nov 2012 repudiation by MJFF.
At the time, he hit the wrong button and published an opposite account of the feelings of the MJFF about MANF. oops.
In other news,
and this is a guess.
The folks in Sweden will get ahold of the MANF IP
The Army will get ahold of the ESS IP in cooperation with Lonza.
Gerald and John will retire from the pharma game. Two companies mismanaged is more than enough.
Gerald will show up as a used car salesman in Ohio. Fall back, a party DJ. Gerald sells a few cars, and has to give up the DJ business.
then one day, I get online, and I HAD BEEN ATTACKED BY THE CEO OF THIS COMPANY.
It seems that someone sort of copied my name, but not quite and everyone believed that he was me.
That is a sign of the level of investor on this board, because I do not talk like that.
At any rate, the attacks by the CEO on this writer should have been a sign that things were bad.
AND it was an excellent sell signal, if you check the chart.
IF YOU CAN ( i DOUBT THAT YOU CAN ) GO SHORT. THAT IS THE ONLY THING TO DO WITH AMBS.
REPEAT AFTER ME, THERE IS NO HOPE FOR THIS COMPANY. Its been a gold mine for whats his face and his dad, and for Sason or whatever his name is.
AND for those who I got to sell at 18 cents.
EVERYONE ELSE LOST MONEY. The company is literally turning out the lights, and you think you should INVEST?
Be my guest, but I would not recommend it.
The fat lady already sung.
The elephant stopped jumping up and down over a year ago. and frankly, I tend to block out people I do not like, and I can't recall that guys name at the moment. He is looking around for a huge compressor to reflate his elephant so it can bounce up and down, like an old acquaintance in business of mine, who had absolutely no clue.
Only the shorts are now making money.
Remember, whats his face reported making 600000 in the year he made all those acquisitions. Everytime he made an acquisition, he gave himself a bonus.
That was your money.
So, Lonza got paid in full for ESS?
Who owns ESS now? AMBS stopped paying on it?
I am most proud of the fact that I got a lot of people OUT at 18 cents. Yea me. ( Pre reverse split )
finally, ESS will get studied, as expected, by another company. Here we come 2017.
I guess it will be Lonza. It will not be AMBS.
The fat lady is signing.
and the elephant is no longer bouncing. The Elephant broke the trampoline about a year ago. ( More or less )